Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $7
JMP Securities analyst Jason Butler maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 39.
Express News | Esperion Secures Additional Commercial and Medicare Formulary Coverage for Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe)
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Esperion Therapeutics Is Maintained at Buy by Needham
Express News | Esperion Therapeutics Inc : Needham Cuts Target Price to $6 From $8